Harpreet Singh‐Jasuja
Immatics Biotechnologies (Germany)(DE)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, vaccines and immunoinformatics approaches, Heat shock proteins research
Most-Cited Works
- → Actively personalized vaccination trial for newly diagnosed glioblastoma(2018)908 cited
- → Cancer classification using the Immunoscore: a worldwide task force(2012)799 cited
- → Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival(2012)779 cited
- → The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 Pathway(2002)484 cited
- → The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor(2000)370 cited
- → Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis(1999)349 cited
- → Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses(2008)283 cited
- → Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein(2002)239 cited
- → IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial(2016)214 cited
- → Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy(2012)200 cited